These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 19085836

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.
    Ghosh S, Koblinski J, Johnson J, Liu Y, Ericsson A, Davis JW, Shi Z, Ravosa MJ, Crawford S, Frazier S, Stack MS.
    Mol Cancer Res; 2010 Feb; 8(2):145-58. PubMed ID: 20145038
    [Abstract] [Full Text] [Related]

  • 3. Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.
    Jiang R, Shi Z, Johnson JJ, Liu Y, Stack MS.
    J Biol Chem; 2011 Mar 18; 286(11):9127-35. PubMed ID: 21163944
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma.
    Johnson JJ, Miller DL, Jiang R, Liu Y, Shi Z, Tarwater L, Williams R, Balsara R, Sauter ER, Stack MS.
    J Biol Chem; 2016 Mar 25; 291(13):6936-45. PubMed ID: 26839311
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M, Rao JS.
    J Biol Chem; 2005 Oct 28; 280(43):36529-40. PubMed ID: 16127174
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN, Hadler-Olsen E, Costea DE, Berg E, Jacobsen CC, Mortensen B, Salo T, Martinez-Zubiaurre I, Winberg JO, Uhlin-Hansen L, Svineng G.
    BMC Cancer; 2017 May 19; 17(1):350. PubMed ID: 28526008
    [Abstract] [Full Text] [Related]

  • 15. γ-Synuclein Expression Is a Malignant Index in Oral Squamous Cell Carcinoma.
    Cheng JC, Chiang MT, Lee CH, Liu SY, Chiu KC, Chou YT, Huang RY, Huang SM, Shieh YS.
    J Dent Res; 2016 Apr 19; 95(4):439-45. PubMed ID: 26661712
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells.
    Liang X, Yang X, Tang Y, Zhou H, Liu X, Xiao L, Gao J, Mao Z.
    Oral Oncol; 2008 Dec 19; 44(12):1172-80. PubMed ID: 18486529
    [Abstract] [Full Text] [Related]

  • 19. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
    Shi Z, Stack MS.
    Biochem J; 2007 Oct 15; 407(2):153-9. PubMed ID: 17880283
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.